The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | JVDF: immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab
Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses the results of the Phase I JVDF study (NCT02443324) which aimed to evaluate the effect of ramucirumab, a VEGF inhibitor, in combination with pembrolizumab. Immune profliling suggests that the inclusion of a VEGF inhibitor increases inflammation within the tumour microenvironment, which may result in increased efficacy compared to checkpoint blockade therapies alone. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
